Zymergen Inc. (ZY) News

Zymergen Inc. (ZY): $2.43

0.04 (+1.67%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Add ZY to Watchlist
Sign Up

Industry: Chemicals

Industry

NR

Ranked

#83 of 88

in industry

Filter ZY News Items

ZY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ZY News From Around the Web

Below are the latest news stories about ZYMERGEN INC that investors may wish to consider to help them evaluate ZY as an investment opportunity.

Ginkgo Bioworks Lifts Guidance After Mixed Q2 Results; Shares Surge

By Yasin Ebrahim

Yahoo | August 15, 2022

Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future

Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.

Yahoo | August 5, 2022

Is Ginkgo Bioworks Putting Its $1.5 Billion Cash Hoard to Good Use?

The synthetic biology leader's healthy cash balance provides plenty of breathing room, but it won't last forever.

Yahoo | August 2, 2022

Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal

Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction. Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo. Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, incl

Yahoo | July 25, 2022

Ginkgo to Acquire Zymergen

Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen stockholders will receive a

Yahoo | July 25, 2022

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

Octant doubles its initial investment in Zymergen’s Automation Technology to significantly increase the scale and throughput of its drug discovery platformEMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficie

Yahoo | July 14, 2022

Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications

EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications. 3D4Makers will convert the powder to filament, offering its first-ever polyimide filament to customers for use across a wide range of applications including aerospace, automotive, and transportation. Polyimide is a very high-strength polymer that is inh

Yahoo | June 28, 2022

Celanese (CE) Soars 6%: Is Further Upside Left in the Stock?

Celanese (CE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | June 27, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investors!

William White on InvestorPlace | June 1, 2022

Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant’s next-generation platform to develop breakthrough medicines. Zymergen’s complete automation solution includes modular hardware, modern web-based software, custom and turnkey workflows, and active monitoring and support. This technology will be incorporated into Octant’s existing

Yahoo | May 26, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!